Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06751979 DDI with Midazolam in Healthy Adults
NCT03126721Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-06751979 in Alzheimer's disease (AD) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve from time 0 to last quantifiable concentration at 24 hours, Maximum Plasma Concentration at 24 hours and 1 more. Started Apr 2017; status: completed.
02
Drugs
PF-06751979
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03126721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126721.